NCT06486883 2026-03-02
PONTIAC
MedSIR
Phase 2 Recruiting
Clinical Trials
42 trialsNCT05424068 2026-02-25
Rehabilitation for People With Advanced Cancer
University Health Network, Toronto
Phase NA Completed
NCT07428655 2026-02-24
Acceptability and Feasibility of PSC Model of Serious Illness Communication
National Cancer Centre, Singapore
Phase NA Active not recruiting
NCT07359404 2026-01-22
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Enrolling by invitation
NCT06612203 2025-12-05
WIN-B
MedSIR
Phase 1/2 Active not recruiting
NCT07259226 2025-12-02
OASIS
UNICANCER
Phase 2 Recruiting
NCT05530057 2025-11-20
ESPERO
Seoul National University Hospital
Phase 2 Recruiting
NCT05831878 2025-11-18
RC48-ADC in HER2-low Advanced Breast Cancer
RenJi Hospital
Phase NA Recruiting
NCT07180082 2025-11-18
CORIN-PYRA
RenJi Hospital
Phase 2 Recruiting
NCT07180160 2025-11-18
ITHRAN
RenJi Hospital
Phase 2 Recruiting
NCT05876065 2025-09-11
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
RenJi Hospital
Phase NA Recruiting
NCT04227327 2025-07-29
HERMIONE-7
University of Milano Bicocca
Phase 2 Terminated
NCT07041437 2025-06-27
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT04892693 2025-04-17
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
Seoul National University Hospital
Phase 2 Recruiting
NCT05536128 2025-04-17
Post-CDK
Seoul National University Hospital
Phase 2 Recruiting
NCT06750848 2024-12-27
Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
Affiliated Cancer Hospital of Shantou University Medical College
Phase 2 Not yet recruiting
NCT06470672 2024-12-20
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT06656624 2024-10-24
Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT03205761 2024-10-18
COMETABreast
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT06447623 2024-06-07
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Fudan University
Phase 3 Recruiting
NCT06433609 2024-05-30
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Beijing GoBroad Hospital
Phase 2 Not yet recruiting
NCT06375707 2024-04-19
Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06125834 2024-04-16
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05861830 2024-03-12
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
Peking Union Medical College Hospital
Phase 3 Recruiting
NCT06290466 2024-03-04
Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects
Ahon Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT04714619 2023-12-19
CAILA
MedSIR
Phase 2 Terminated
NCT02599363 2023-11-09
A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT04304352 2023-06-28
VEX
European Institute of Oncology
Phase 2 Unknown
NCT02027376 2023-04-03
EDALINE
Spanish Breast Cancer Research Group
Phase 1 Completed
NCT04826016 2023-03-20
POLTER
MedSIR
Phase 1/2 Withdrawn
NCT03931551 2023-02-22
OPHELIA
MedSIR
Phase 2 Terminated
NCT05469750 2022-07-22
Dalpiciclib Plus Letrozole and Capecitabine
Fujian Medical University Union Hospital
Phase 2 Unknown
NCT05439499 2022-07-06
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT05438810 2022-07-05
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT05431504 2022-06-24
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT03071926 2022-04-20
Metronomic PLD in Patients With Primary Endocrine Resistant ABC
Fudan University
Phase 2 Unknown
NCT05255523 2022-02-24
Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer
Fujian Medical University Union Hospital
Phase 2 Unknown
NCT05047848 2021-09-17
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
Liaoning Cancer Hospital & Institute
Phase NA Unknown
NCT03240224 2019-01-25
Bioinformation Therapy for Breast Cancer
Fuda Cancer Hospital, Guangzhou
Phase 2/3 Completed
NCT03182634 2019-01-22
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT03405168 2018-11-16
Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT00719875 2017-03-03
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Yale University
Phase 1 Completed